BioSpace News Archive

DexCom, Inc. has updated its first quarter 2022 earnings call due to technical difficulties with the conference call provider. The conference call will now start at 5:30 p.m. (Eastern Time).

Nortech Systems Incorporated (Nasdaq: NSYS) (the “Company”) a global leader in specialized design and manufacturing solutions for complex electrical and electromedical components, announced this week the launch of its newest active optical technology platform, Active Optical Xtreme (AOX).

Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, provided an activity report for the third quarter ended March 31, 2022.

Transcenta Holding Limited announces that the abstracts of TST001 and MSB0254 have been accepted by the 2022 annual meeting of American Society of Clinical Oncology.

Finch Therapeutics Group, Inc. announced that the U.S. Food and Drug Administration has removed the clinical hold on Finch’s investigational new drug application for CP101.

Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Camzyos™ (mavacamten, 2.5 mg, 5 mg, 10 mg, 15 mg capsules) for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (obstructive HCM) to improve functional capacity and symptoms.

HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the pricing of its upsized initial public offering of 11,765,000 shares of common stock at an initial public offering price of $17.00 per share.